CA2438504C - Treatment of solid tumours with rapamycin derivatives - Google Patents

Treatment of solid tumours with rapamycin derivatives Download PDF

Info

Publication number
CA2438504C
CA2438504C CA2438504A CA2438504A CA2438504C CA 2438504 C CA2438504 C CA 2438504C CA 2438504 A CA2438504 A CA 2438504A CA 2438504 A CA2438504 A CA 2438504A CA 2438504 C CA2438504 C CA 2438504C
Authority
CA
Canada
Prior art keywords
compound
administered
combination
formula
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
CA2438504A
Other languages
English (en)
French (fr)
Other versions
CA2438504A1 (en
Inventor
Heidi Lane
Terence O'reilly
Jeanette Marjorie Wood
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26245731&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CA2438504(C) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0104072A external-priority patent/GB0104072D0/en
Priority claimed from GB0124957A external-priority patent/GB0124957D0/en
Application filed by Novartis AG filed Critical Novartis AG
Priority to CA2860306A priority Critical patent/CA2860306C/en
Publication of CA2438504A1 publication Critical patent/CA2438504A1/en
Application granted granted Critical
Publication of CA2438504C publication Critical patent/CA2438504C/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/451—Non condensed piperidines, e.g. piperocaine having a carbocyclic group directly attached to the heterocyclic ring, e.g. glutethimide, meperidine, loperamide, phencyclidine, piminodine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Otolaryngology (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
CA2438504A 2001-02-19 2002-02-18 Treatment of solid tumours with rapamycin derivatives Expired - Lifetime CA2438504C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2860306A CA2860306C (en) 2001-02-19 2002-02-18 Treatment of solid tumors with rapamycin derivatives

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB0104072.4 2001-02-19
GB0104072A GB0104072D0 (en) 2001-02-19 2001-02-19 Organic compounds
GB0124957A GB0124957D0 (en) 2001-10-17 2001-10-17 Organic compounds
GB0124957.2 2001-10-17
PCT/EP2002/001714 WO2002066019A2 (en) 2001-02-19 2002-02-18 Cancer treatment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2860306A Division CA2860306C (en) 2001-02-19 2002-02-18 Treatment of solid tumors with rapamycin derivatives

Publications (2)

Publication Number Publication Date
CA2438504A1 CA2438504A1 (en) 2002-08-29
CA2438504C true CA2438504C (en) 2016-02-16

Family

ID=26245731

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2438504A Expired - Lifetime CA2438504C (en) 2001-02-19 2002-02-18 Treatment of solid tumours with rapamycin derivatives
CA2994779A Expired - Lifetime CA2994779C (en) 2001-02-19 2002-02-18 Use of 40-o-(2-hydroxyethyl)-rapamycin for inhibiting growth of a solid tumour of the brain other than lymphatic cancer
CA2860306A Expired - Lifetime CA2860306C (en) 2001-02-19 2002-02-18 Treatment of solid tumors with rapamycin derivatives

Family Applications After (2)

Application Number Title Priority Date Filing Date
CA2994779A Expired - Lifetime CA2994779C (en) 2001-02-19 2002-02-18 Use of 40-o-(2-hydroxyethyl)-rapamycin for inhibiting growth of a solid tumour of the brain other than lymphatic cancer
CA2860306A Expired - Lifetime CA2860306C (en) 2001-02-19 2002-02-18 Treatment of solid tumors with rapamycin derivatives

Country Status (27)

Country Link
US (10) US8410131B2 (enExample)
EP (11) EP3406249A1 (enExample)
JP (14) JP2004525899A (enExample)
KR (3) KR20050095906A (enExample)
CN (5) CN104083365A (enExample)
AU (1) AU2002250968C1 (enExample)
BR (1) BR0207378A (enExample)
CA (3) CA2438504C (enExample)
CY (11) CY1116616T1 (enExample)
CZ (5) CZ307940B6 (enExample)
DK (6) DK3351246T3 (enExample)
ES (8) ES2921798T3 (enExample)
HK (2) HK1250018B (enExample)
HU (1) HUP0303271A3 (enExample)
IL (13) IL157425A0 (enExample)
LT (9) LT2269604T (enExample)
LU (3) LU92880I2 (enExample)
MX (3) MX368013B (enExample)
NO (14) NO333105B1 (enExample)
NZ (1) NZ527692A (enExample)
PL (5) PL414997A1 (enExample)
PT (7) PT3143995T (enExample)
RU (8) RU2322981C2 (enExample)
SI (6) SI3351246T1 (enExample)
SK (5) SK288546B6 (enExample)
TW (2) TWI334350B (enExample)
WO (1) WO2002066019A2 (enExample)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
IL144144A0 (en) 1999-01-13 2002-05-23 Bayer Ag Omega-carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
CA2438504C (en) 2001-02-19 2016-02-16 Novartis Ag Treatment of solid tumours with rapamycin derivatives
PL367267A1 (en) * 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
SI1478358T1 (sl) 2002-02-11 2013-09-30 Bayer Healthcare Llc Sorafenib tozilat za zdravljenje bolezni, značilnih po abnormalni angiogenezi
US8383605B2 (en) * 2002-07-30 2013-02-26 Aeterna Zentaris Gmbh Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals
WO2004012744A1 (de) * 2002-07-30 2004-02-12 Zentaris Gmbh Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten
US7846141B2 (en) 2002-09-03 2010-12-07 Bluesky Medical Group Incorporated Reduced pressure treatment system
AU2003264822A1 (en) * 2002-10-11 2004-05-04 Dana-Farber Cancer Institute Inc Epothilone derivatives for the treatment of multiple myeloma
US7557129B2 (en) 2003-02-28 2009-07-07 Bayer Healthcare Llc Cyanopyridine derivatives useful in the treatment of cancer and other disorders
UA83484C2 (uk) * 2003-03-05 2008-07-25 Уайт Спосіб лікування раку грудей комбінацією похідного рапаміцину і інгібітора ароматази - летрозолу, фармацевтична композиція
JP4860474B2 (ja) 2003-05-20 2012-01-25 バイエル、ファーマシューテイカルズ、コーポレイション Ｐｄｇｆｒによって仲介される病気のためのジアリール尿素
CL2004001834A1 (es) 2003-07-23 2005-06-03 Bayer Pharmaceuticals Corp Compuesto 4-{4-[3-(4-cloro-3-trifluorometilfenil)-ureido]-3-fluorofenoxi}-piridin-2-metilamida, inhibidor de la raf, vegfr, p38 y pdgfr quinasas, sus sales; composiicon farmaceutica; combinacion farmaceutica; y su uso para tratar trastornos hiperprol
CN102144961A (zh) 2003-09-18 2011-08-10 参天制药株式会社 经巩膜递送
ES2494915T3 (es) * 2004-02-23 2014-09-16 Novartis Ag P53 natural como biomarcador para el tratamiento con inhibidores de mTOR en combinación con un agente citotóxico
WO2005092384A2 (en) * 2004-03-23 2005-10-06 Astrazeneca Ab Combination therapy with azd2171 and a platinum anti-tumour agent
GB0406446D0 (en) * 2004-03-23 2004-04-28 Astrazeneca Ab Combination therapy
EP1853259A1 (en) 2005-02-09 2007-11-14 Macusight, Inc. Formulations for ocular treatment
NZ577283A (en) * 2005-03-07 2010-11-26 Robarts Res Inst Use of a Myxoma virus that does not express functional M135R
GB0504995D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
GB0504994D0 (en) * 2005-03-11 2005-04-20 Biotica Tech Ltd Novel compounds
US20100061994A1 (en) * 2005-03-11 2010-03-11 Rose Mary Sheridan Medical uses of 39-desmethoxyrapamycin and analogues thereof
GB0507918D0 (en) 2005-04-19 2005-05-25 Novartis Ag Organic compounds
KR20080041206A (ko) * 2005-07-20 2008-05-09 노파르티스 아게 피리미딜아미노벤즈아미드와 ｍｔｏｒ 키나제 억제제의조합물
EP1962839A4 (en) 2005-11-14 2010-08-25 Ariad Pharma Inc ADMINISTRATION OF A MNTOR INHIBITOR FOR THE TREATMENT OF PATIENTS WITH CANCER
NZ568182A (en) 2005-11-21 2010-08-27 Novartis Ag Neuroendocrine tumor treatment using MTOR inhibitors
GB0602123D0 (en) * 2006-02-02 2006-03-15 Novartis Ag Organic compounds
BRPI0707684B1 (pt) 2006-02-02 2021-10-13 Novartis Ag Uso de 40-o-(2-hidroxietil)-rapamicina para fabricar medicamento para tratar distúrbios mediados pelo complexo de esclerose tuberosa
EP2001438A2 (en) 2006-02-09 2008-12-17 Macusight, Inc. Stable formulations, and methods of their preparation and use
EP2001466B1 (en) 2006-03-23 2016-01-06 Santen Pharmaceutical Co., Ltd Low-dose rapamycin for the treatment of vascular permeability-related diseases
KR20080108517A (ko) * 2006-04-05 2008-12-15 노파르티스 아게 암을 치료하기 위한 치료제의 조합물
US20080085874A1 (en) * 2006-08-28 2008-04-10 The Regents Of The University Of California Small molecule potentiator of hormonal therapy for breast cancer
US9820888B2 (en) 2006-09-26 2017-11-21 Smith & Nephew, Inc. Wound dressing
KR20090118999A (ko) * 2007-03-07 2009-11-18 아브락시스 바이오사이언스, 엘엘씨 항암제로서 라파마이신 및 알부민을 포함하는 나노입자
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
CN101292980B (zh) * 2007-04-28 2010-11-10 上海交通大学医学院附属仁济医院 一种含有雷帕霉素的用于治疗大肠癌的药物组合物
ES2706023T3 (es) * 2007-08-16 2019-03-27 Biocompatibles Uk Ltd Administración de combinaciones de fármacos
WO2009058895A1 (en) * 2007-10-30 2009-05-07 Syndax Pharmaceuticals, Inc. Administration of an inhibitor of hdac and an mtor inhibitor
US8298200B2 (en) 2009-06-01 2012-10-30 Tyco Healthcare Group Lp System for providing continual drainage in negative pressure wound therapy
US20120040896A1 (en) * 2008-04-11 2012-02-16 The Regents Of The University Of Colorado Compositions, methods and uses for modulation of brca 1
JP5787757B2 (ja) * 2008-08-04 2015-09-30 ファイブ プライム セラピューティックス インコーポレイテッド Ｆｇｆｒ細胞外ドメイン酸性領域突然変異タンパク質
GB0902368D0 (en) 2009-02-13 2009-04-01 Smith & Nephew Wound packing
GB0922332D0 (en) 2009-12-22 2010-02-03 Isis Innovation Method of treatment and screening method
US8791315B2 (en) 2010-02-26 2014-07-29 Smith & Nephew, Inc. Systems and methods for using negative pressure wound therapy to manage open abdominal wounds
CA2794513A1 (en) 2010-03-31 2011-10-06 Aeterna Zentaris Gmbh Perifosine and capecitabine as a combined treatment for cancer
PT2606070T (pt) 2010-08-20 2017-03-31 Novartis Ag Anticorpos para o recetor 3 do fator de crescimento epidérmico (her3)
EP3590538A1 (en) 2011-12-05 2020-01-08 Novartis AG Antibodies for epidermal growth factor receptor 3 (her3)
AU2013264934B2 (en) 2012-05-23 2017-07-20 Smith & Nephew Plc Apparatuses and methods for negative pressure wound therapy
BR112015002154A2 (pt) 2012-08-01 2017-07-04 Smith & Nephew curativo de ferimento
CN108186200B (zh) 2012-08-01 2021-08-10 史密夫及内修公开有限公司 伤口敷料
US10493184B2 (en) 2013-03-15 2019-12-03 Smith & Nephew Plc Wound dressing and method of treatment
US10682415B2 (en) 2013-07-22 2020-06-16 Wisconsin Alumni Research Foundation Thermogel formulation for combination drug delivery
WO2016066608A1 (en) 2014-10-28 2016-05-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for treatment of pulmonary cell senescence and peripheral aging
JP6623745B2 (ja) * 2015-06-29 2019-12-25 富士通株式会社 電子回路及び発振器の制御方法
SMT201900452T1 (it) * 2015-08-17 2019-11-13 Kura Oncology Inc Metodi di trattamento di pazienti di cancro con inibitori di farnesil trasferasi
EA201892051A1 (ru) * 2016-03-15 2019-02-28 Тайм, Инк. Фармацевтические композиции для лечения злокачественного новообразования
US20200081010A1 (en) 2016-12-02 2020-03-12 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and compositions for diagnosing renal cell carcinoma
WO2018129533A1 (en) 2017-01-09 2018-07-12 Shuttle Pharmaceuticals, Llc Selective histone deacetylase inhibitors for the treatment of human disease
US11584733B2 (en) 2017-01-09 2023-02-21 Shuttle Pharmaceuticals, Inc. Selective histone deacetylase inhibitors for the treatment of human disease
CA3066082A1 (en) 2017-06-30 2019-01-03 T. J. Smith & Nephew,Limited Negative pressure wound therapy apparatus
UY37900A (es) 2017-09-26 2019-04-30 Novartis Ag Nuevos derivados de rapamicina
WO2019089556A1 (en) * 2017-10-31 2019-05-09 Steve Gorlin Combinations of chemotherapeutic agents and antimicrobial particles and uses thereof
ES2983284T3 (es) 2018-01-09 2024-10-22 Shuttle Pharmaceuticals Inc Inhibidores selectivos de histona deacetilasa para el tratamiento de enfermedades humanas
WO2019212991A1 (en) 2018-05-01 2019-11-07 Revolution Medicines, Inc. C26-linked rapamycin analogs as mtor inhibitors
CR20240382A (es) 2018-05-01 2025-08-29 Revolution Medicines Inc ANÁLOGOS DE RAPAMICINA A C40, C28 Y C32 COMO INHIBIDORES DE MTOR (Divisional 2020-578)
CN108825638A (zh) * 2018-08-01 2018-11-16 安徽送变电工程有限公司 一种应用于螺纹工件的防盗装置
RS66527B1 (sr) 2018-12-18 2025-03-31 Novartis Ag Derivati rapamicina
GB201905780D0 (en) 2019-04-25 2019-06-05 La Thangue Nicholas Cancer therapy
PH12021552866A1 (en) 2019-05-14 2022-11-07 Tyme Inc Compositions and methods for treating cancer
US10905698B1 (en) 2020-05-14 2021-02-02 Tyme, Inc. Methods of treating SARS-COV-2 infections
KR20230053539A (ko) 2021-10-14 2023-04-21 (주)파로스아이바이오 2,3,5-치환된 싸이오펜 화합물을 포함하는 병용 투여용 조성물
JP2025522296A (ja) 2022-05-25 2025-07-15 レヴォリューション・メディスンズ，インコーポレイテッド ｍＴＯＲ阻害剤によりがんを処置する方法

Family Cites Families (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US876165A (en) 1904-05-11 1908-01-07 George K Woodworth Wireless telegraph transmitting system.
GB104072A (en) 1916-04-14 1917-02-22 William Henry Nosworthy Apparatus for Lighting Fires or Heating or other purposes.
GB124957A (en) 1918-06-04 1919-04-10 Frederick William Miller Improvement in Glass Moulding.
GB1524747A (en) 1976-05-11 1978-09-13 Ici Ltd Polypeptide
US5066493A (en) * 1978-11-03 1991-11-19 American Home Products Corporation Rapamycin in treatment of tumors
US4885171A (en) * 1978-11-03 1989-12-05 American Home Products Corporation Use of rapamycin in treatment of certain tumors
US5206018A (en) * 1978-11-03 1993-04-27 Ayerst, Mckenna & Harrison, Inc. Use of rapamycin in treatment of tumors
BE877700A (fr) * 1978-11-03 1980-01-14 Ayerst Mckenna & Harrison Compositions pharmaceutiques a base de rapamycine pour le traitement de tumeurs carcinogenes
LU88769I2 (fr) 1982-07-23 1996-11-05 Zeneca Ltd Bicalutamide et ses sels et esters pharmaceutiquement acceptables (Casodex (R))
GB8327256D0 (en) 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
GB8517360D0 (en) 1985-07-09 1985-08-14 Erba Farmitalia Substituted androsta-1,4-diene-3,17-diones
IL86632A0 (en) 1987-06-15 1988-11-30 Ciba Geigy Ag Derivatives substituted at methyl-amino nitrogen
US5093330A (en) * 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
US5010099A (en) * 1989-08-11 1991-04-23 Harbor Branch Oceanographic Institution, Inc. Discodermolide compounds, compositions containing same and method of preparation and use
US5194447A (en) * 1992-02-18 1993-03-16 American Home Products Corporation Sulfonylcarbamates of rapamycin
NZ243082A (en) 1991-06-28 1995-02-24 Ici Plc 4-anilino-quinazoline derivatives; pharmaceutical compositions, preparatory processes, and use thereof
AU661533B2 (en) 1992-01-20 1995-07-27 Astrazeneca Ab Quinazoline derivatives
JP3140228B2 (ja) * 1992-02-17 2001-03-05 ファイザー製薬株式会社 新規な大環状ラクトンおよびその生産菌
US5521184A (en) * 1992-04-03 1996-05-28 Ciba-Geigy Corporation Pyrimidine derivatives and processes for the preparation thereof
TW225528B (enExample) 1992-04-03 1994-06-21 Ciba Geigy Ag
US5256790A (en) * 1992-08-13 1993-10-26 American Home Products Corporation 27-hydroxyrapamycin and derivatives thereof
GB9221220D0 (en) * 1992-10-09 1992-11-25 Sandoz Ag Organic componds
WO1994009019A1 (en) 1992-10-14 1994-04-28 Unichema Chemie B.V. Process for the preparation of alkylglycosides
DK1238986T3 (da) 1992-10-28 2008-09-29 Genentech Inc Anvendelse af antagonister mod vaskulær endotelcellevækstfaktor
US5258389A (en) * 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
GB2273704B (en) * 1992-12-16 1997-01-22 Orion Yhtymae Oy Triazolyl diaryl selective aromatase inhibiting compounds
DE4301781C2 (de) 1993-01-23 1995-07-20 Lohmann Therapie Syst Lts Nitroglycerinhaltiges Pflaster, Verfahren zu seiner Herstellung und Verwendung
GB9314893D0 (en) 1993-07-19 1993-09-01 Zeneca Ltd Quinazoline derivatives
US5387680A (en) * 1993-08-10 1995-02-07 American Home Products Corporation C-22 ring stabilized rapamycin derivatives
WO1995014023A1 (en) 1993-11-19 1995-05-26 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
GB9325400D0 (en) 1993-12-11 1994-02-16 Sarll David P G Temperature recorder
ATE191218T1 (de) 1993-12-17 2000-04-15 Novartis Ag Rapamycin-derivate als immunosuppressoren
WO1995028156A1 (en) * 1994-04-14 1995-10-26 Sepracor, Inc. Treating estrogen-dependent diseases with (-)-fadrozole
US5362718A (en) 1994-04-18 1994-11-08 American Home Products Corporation Rapamycin hydroxyesters
GB9417873D0 (en) 1994-09-06 1994-10-26 Sandoz Ltd Organic compounds
PE52896A1 (es) 1994-10-26 1996-12-12 Novartis Ag Composicion farmaceutica
ES2332984T3 (es) 1995-03-30 2010-02-16 Pfizer Products Inc. Derivados de quinazolinas.
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
US5747498A (en) 1996-05-28 1998-05-05 Pfizer Inc. Alkynyl and azido-substituted 4-anilinoquinazolines
US5880141A (en) 1995-06-07 1999-03-09 Sugen, Inc. Benzylidene-Z-indoline compounds for the treatment of disease
US5843901A (en) 1995-06-07 1998-12-01 Advanced Research & Technology Institute LHRH antagonist peptides
PL184731B1 (pl) * 1995-06-09 2002-12-31 Novartis Ag Pochodne rapamycyny, zastosowanie pochodnych rapamycyny i kompozycja farmaceutyczna
WO1997002266A1 (en) 1995-07-06 1997-01-23 Novartis Ag Pyrrolopyrimidines and processes for the preparation thereof
US5567831A (en) * 1995-08-16 1996-10-22 Duguesne University Of The Holy Ghost Non-steroidal sulfatase inhibitor compounds and their method of use
US6245805B1 (en) * 1995-10-26 2001-06-12 Baker Norton Pharmaceuticals, Inc. Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
DE19544507B4 (de) 1995-11-29 2007-11-15 Novartis Ag Cyclosporin enthaltende Präparate
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
US5760041A (en) 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9606452D0 (en) * 1996-03-27 1996-06-05 Sandoz Ltd Organic compounds
CN1923818A (zh) 1996-04-12 2007-03-07 沃尼尔·朗伯公司 酪氨酸激酶的不可逆抑制剂
DK0896544T3 (da) * 1996-06-11 2003-05-05 Novartis Ag Kombination af en somatostatinanalog og en rapamycin
WO1997049688A1 (en) 1996-06-24 1997-12-31 Pfizer Inc. Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
US6492330B1 (en) * 1996-08-16 2002-12-10 National Institute Of Immunology Antiangiogenic drugs
US5922730A (en) 1996-09-09 1999-07-13 American Home Products Corporation Alkylated rapamycin derivatives
EP0927182A2 (en) 1996-09-09 1999-07-07 American Home Products Corporation Alkylated rapamycin derivatives
DE19638745C2 (de) 1996-09-11 2001-05-10 Schering Ag Monoklonale Antikörper gegen die extrazelluläre Domäne des menschlichen VEGF - Rezeptorproteins (KDR)
WO1998010767A2 (en) 1996-09-13 1998-03-19 Sugen, Inc. Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
GB9619631D0 (en) * 1996-09-20 1996-11-06 British Biotech Pharm Combination therapy
EP0837063A1 (en) 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
US5985325A (en) 1997-06-13 1999-11-16 American Home Products Corporation Rapamycin formulations for oral administration
CO4940418A1 (es) 1997-07-18 2000-07-24 Novartis Ag Modificacion de cristal de un derivado de n-fenil-2- pirimidinamina, procesos para su fabricacion y su uso
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
GB9721069D0 (en) 1997-10-03 1997-12-03 Pharmacia & Upjohn Spa Polymeric derivatives of camptothecin
US6152347A (en) 1998-01-30 2000-11-28 Acco Brands, Inc. Vertical Stapler
DK2198858T3 (da) 1998-03-26 2011-10-03 Astellas Pharma Inc Præparat med opretholdt frigivelse af en makrolidforbindelse såsom tacrolimus
US8029561B1 (en) * 2000-05-12 2011-10-04 Cordis Corporation Drug combination useful for prevention of restenosis
KR100406823B1 (ko) * 1998-04-27 2003-11-21 후지사와 야꾸힝 고교 가부시키가이샤 의약 조성물
DE69942097D1 (de) 1998-08-11 2010-04-15 Novartis Ag Isochinoline derivate mit angiogenesis-hemmender wirkung
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
UA71587C2 (uk) 1998-11-10 2004-12-15 Шерінг Акцієнгезелльшафт Аміди антранілової кислоти та їхнє застосування як лікарських засобів
IL143596A0 (en) 1998-12-22 2002-04-21 Genentech Inc Vascular endothelial cell growth factor antagonists and uses thereof
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
EP1165085B1 (en) 1999-03-30 2006-06-14 Novartis AG Phthalazine derivatives for treating inflammatory diseases
US6333348B1 (en) * 1999-04-09 2001-12-25 Aventis Pharma S.A. Use of docetaxel for treating cancers
GB9911582D0 (en) * 1999-05-18 1999-07-21 Pharmacia & Upjohn Spa Combined method of treatment comprising an aromatase inhibitor and a further biologically active compound
EP1074265A1 (en) 1999-08-03 2001-02-07 Erasmus Universiteit Rotterdam Use of AMH and/or AMH agonists and/or AMH antagonists for long-term control of female fertility
ATE271052T1 (de) 1999-08-18 2004-07-15 Wyeth Corp Wasserlösliche sdz-rad ester
WO2001045740A2 (en) 1999-12-22 2001-06-28 The Government Of The United States, Department Of Health And Human Services Compositions and methods for treatment of breast cancer
WO2001049338A1 (en) 1999-12-30 2001-07-12 Li Wei Pin Controlled delivery of therapeutic agents by insertable medical devices
WO2001051049A1 (en) 2000-01-14 2001-07-19 The Trustees Of The University Of Pennsylvania O-methylated rapamycin derivatives for alleviation and inhibition of lymphoproliferative disorders
US6641811B1 (en) * 2000-02-10 2003-11-04 Cornell Research Foundation, Inc. Use of angiotensin II inhibitors to prevent malignancies associated with immunosuppression
GB0005257D0 (en) 2000-03-03 2000-04-26 Pharmacia & Upjohn Spa Breast cancer hormonal therapy
US6761895B2 (en) 2000-04-17 2004-07-13 Yamanouchi Pharmaceutical Co., Ltd. Drug delivery system for averting pharmacokinetic drug interaction and method thereof
US20020013335A1 (en) * 2000-06-16 2002-01-31 American Home Products Corporation Method of treating cardiovascular disease
GB0017635D0 (en) 2000-07-18 2000-09-06 Pharmacia & Upjohn Spa Antitumor combined therapy
ES2228932T3 (es) * 2000-08-11 2005-04-16 Wyeth Procedimiento de tratamiento del carcinoma positivo de estrogenos.
WO2002022133A1 (en) * 2000-09-12 2002-03-21 Virginia Commonwealth University Promotion of adoptosis in cancer cells by co-administration of cyclin dependent kinase inhibitors and cellular differentiation agents
US6696483B2 (en) * 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
ATE367836T1 (de) 2000-10-31 2007-08-15 Cook Inc Beschichtete, implantierbare medizinische geräte
TWI286074B (en) 2000-11-15 2007-09-01 Wyeth Corp Pharmaceutical composition containing CCI-779 as an antineoplastic agent
ATE369817T1 (de) * 2000-12-22 2007-09-15 Avantec Vascular Corp Vorrichtung zur abgabe von therapeutischen wirkstoffen
US20020151508A1 (en) * 2001-02-09 2002-10-17 Schering Corporation Methods for treating proliferative diseases
CA2438504C (en) 2001-02-19 2016-02-16 Novartis Ag Treatment of solid tumours with rapamycin derivatives
EP1385551B1 (en) 2001-04-06 2008-09-03 Wyeth Antineoplastic combinations comprising cci-779 (rapamycin derivative) together with gemcitabine or fluorouracil
PL367267A1 (en) 2001-06-01 2005-02-21 Wyeth Antineoplastic combinations
UA77200C2 (en) 2001-08-07 2006-11-15 Wyeth Corp Antineoplastic combination of cci-779 and bkb-569
US7488313B2 (en) 2001-11-29 2009-02-10 Boston Scientific Scimed, Inc. Mechanical apparatus and method for dilating and delivering a therapeutic agent to a site of treatment
JP2003330447A (ja) 2002-05-15 2003-11-19 Mitsubishi Electric Corp 画像処理装置
NZ568182A (en) 2005-11-21 2010-08-27 Novartis Ag Neuroendocrine tumor treatment using MTOR inhibitors
CN103619402B (zh) 2011-07-01 2017-05-03 科洛普拉斯特公司 具有球囊的导管
EP2606816A1 (en) 2011-12-22 2013-06-26 Koninklijke Philips Electronics N.V. A method and system for providing an indication as to the amount of milk remaining in a breast during lactation

Also Published As

Publication number Publication date
CY1121983T1 (el) 2020-05-29
LT2762140T (lt) 2017-06-26
NO336581B1 (no) 2015-09-28
TW200626151A (en) 2006-08-01
HK1250336B (en) 2020-02-07
AU2002250968C1 (en) 2018-01-04
US20130287769A1 (en) 2013-10-31
HUP0303271A2 (hu) 2004-01-28
RU2011138835A (ru) 2013-03-27
CN104083365A (zh) 2014-10-08
SI2762140T1 (sl) 2017-07-31
SI3143995T1 (sl) 2019-02-28
EP3342411A1 (en) 2018-07-04
IL229158A (en) 2017-03-30
PL409579A1 (pl) 2015-03-02
TWI334350B (en) 2010-12-11
IL202155A0 (en) 2010-06-16
KR100695846B9 (ko) 2021-09-30
US20130253000A1 (en) 2013-09-26
US20130296359A1 (en) 2013-11-07
PL414996A1 (pl) 2016-02-29
CY1119029T1 (el) 2018-01-10
SK10382003A3 (sk) 2004-03-02
NO20161348A1 (no) 2016-08-24
IL220095A (en) 2017-05-29
NO20150831A1 (no) 2015-06-24
NO333105B1 (no) 2013-03-04
DK2762140T3 (en) 2017-07-10
EP2269603A1 (en) 2011-01-05
WO2002066019A2 (en) 2002-08-29
CN104116738A (zh) 2014-10-29
PT2269603E (pt) 2015-09-09
JP2014177469A (ja) 2014-09-25
JP6349475B2 (ja) 2018-06-27
SK288524B6 (sk) 2018-01-04
LU92880I2 (fr) 2016-11-17
JP2018100283A (ja) 2018-06-28
IL229157A0 (en) 2013-12-31
IL220096A0 (en) 2012-07-31
JP5879391B2 (ja) 2016-03-08
NO20033651L (no) 2003-10-17
JP6349474B2 (ja) 2018-06-27
IL220095A0 (en) 2012-07-31
JP2016222705A (ja) 2016-12-28
JP2014208657A (ja) 2014-11-06
DK3342411T3 (da) 2019-09-02
LU93320I2 (fr) 2017-01-30
IL220096A (en) 2015-10-29
NO20131547L (no) 2003-10-17
LTPA2019511I1 (lt) 2019-06-25
NZ527692A (en) 2005-05-27
IL259724B (en) 2021-12-01
KR20040007451A (ko) 2004-01-24
SI3342411T1 (sl) 2019-10-30
JP2018168188A (ja) 2018-11-01
NO20120451L (no) 2003-10-17
US8436010B2 (en) 2013-05-07
CY1118316T1 (el) 2017-04-05
IL250676A0 (en) 2017-03-30
IL229160A0 (en) 2013-12-31
PT3342411T (pt) 2019-09-19
NO340924B1 (no) 2017-07-17
US20140105895A1 (en) 2014-04-17
US20130059877A1 (en) 2013-03-07
EP2269604B1 (en) 2016-07-27
ES2543383T3 (es) 2015-08-18
CY2016047I1 (el) 2017-04-05
IL157425A0 (en) 2004-03-28
NO20150413L (no) 2003-10-17
JP2004525899A (ja) 2004-08-26
RU2006140514A (ru) 2008-05-27
CZ307940B6 (cs) 2019-09-04
AU2002250968B2 (en) 2006-01-12
SK288545B6 (sk) 2018-03-05
KR20070102762A (ko) 2007-10-19
NO20190290A1 (no) 2003-10-17
JP6383814B2 (ja) 2018-08-29
NO20131545L (no) 2003-10-17
NO339240B1 (no) 2016-11-21
RU2325906C2 (ru) 2008-06-10
CN1296043C (zh) 2007-01-24
HK1198946A1 (en) 2015-06-19
NO336428B1 (no) 2015-08-17
NO20131546L (no) 2003-10-17
US8877771B2 (en) 2014-11-04
PL363918A1 (pl) 2004-11-29
KR20050095906A (ko) 2005-10-04
JP6349476B2 (ja) 2018-06-27
ES2705016T3 (es) 2019-03-21
CN104274442A (zh) 2015-01-14
HK1146245A1 (en) 2011-05-27
RU2013143306A (ru) 2015-03-27
JP2014193901A (ja) 2014-10-09
EP2269604A1 (en) 2011-01-05
SK288630B6 (sk) 2019-01-08
JP2015145411A (ja) 2015-08-13
HK1146247A1 (en) 2011-05-27
US20120283285A1 (en) 2012-11-08
IL157425A (en) 2013-10-31
MX368013B (es) 2019-09-13
DK3351246T3 (da) 2019-06-03
EP2783686A8 (en) 2015-03-04
CY2019043I1 (el) 2020-05-29
RU2003127391A (ru) 2005-03-27
ES2921798T3 (es) 2022-08-31
EP2783686B1 (en) 2017-06-21
JP2020143134A (ja) 2020-09-10
CN1679559A (zh) 2005-10-12
PT3351246T (pt) 2019-06-07
CY2015044I1 (el) 2017-03-15
RU2659725C2 (ru) 2018-07-03
EP3143995A1 (en) 2017-03-22
LT3351246T (lt) 2019-07-10
CZ309178B6 (cs) 2022-04-20
RU2013119705A (ru) 2014-11-10
IL229159A0 (en) 2013-12-31
JP5873128B2 (ja) 2016-03-01
RU2005105664A (ru) 2006-08-10
CY1121715T1 (el) 2020-05-29
HK1250018B (en) 2020-04-17
ES2640787T3 (es) 2017-11-06
IL251270A0 (en) 2017-06-29
RU2322981C2 (ru) 2008-04-27
US20130244951A1 (en) 2013-09-19
RU2445093C2 (ru) 2012-03-20
CY1116616T1 (el) 2017-03-15
ES2629317T3 (es) 2017-08-08
NO20170803A1 (no) 2003-10-17
EP2269603B1 (en) 2015-05-20
EP3351246A1 (en) 2018-07-25
EP3351246B1 (en) 2019-05-22
EP3143995B2 (en) 2025-01-15
DK3143995T3 (en) 2019-01-28
US8778962B2 (en) 2014-07-15
IL250676B (en) 2018-06-28
ES2728739T3 (es) 2019-10-28
JP2017081979A (ja) 2017-05-18
PT2762140T (pt) 2017-07-04
SK288834B6 (sk) 2021-03-10
CA2860306A1 (en) 2002-08-29
CY1121314T1 (el) 2020-05-29
EP2762140B1 (en) 2017-03-22
JP6904640B2 (ja) 2021-07-21
CZ200591A3 (cs) 2019-01-23
CZ307637B6 (cs) 2019-01-23
SI3351246T1 (sl) 2019-08-30
ES2744377T3 (es) 2020-02-24
JP2018100281A (ja) 2018-06-28
NO340553B1 (no) 2017-05-08
IL202155A (en) 2013-04-30
US20160303092A1 (en) 2016-10-20
CY2015044I2 (el) 2017-03-15
IL259724A (en) 2018-08-30
PT2269604T (pt) 2016-11-04
PL415000A1 (pl) 2016-02-29
EP3345602B1 (en) 2022-04-06
EP2762140A1 (en) 2014-08-06
MXPA03007418A (es) 2003-11-18
CY2020005I1 (el) 2020-05-29
CZ309247B6 (cs) 2022-06-22
NO334646B1 (no) 2014-05-05
WO2002066019A3 (en) 2002-10-24
HK1197723A1 (en) 2015-02-13
NO20131544L (no) 2003-10-17
JP2018100282A (ja) 2018-06-28
SK902019A3 (enExample) 2004-03-02
ES2600304T3 (es) 2017-02-08
LT3143995T (lt) 2019-01-25
LTC2269604I2 (lt) 2020-01-27
NO20130045L (no) 2003-10-17
LTPA2016035I1 (lt) 2016-12-27
LUC00122I1 (enExample) 2019-06-06
LUC00122I2 (enExample) 2019-12-24
RU2018121314A3 (enExample) 2021-10-06
EP2764865A2 (en) 2014-08-13
RU2018127821A (ru) 2020-01-30
PT3345602T (pt) 2022-07-04
CZ20032209A3 (cs) 2004-01-14
EP3143995B1 (en) 2018-12-05
JP5775022B2 (ja) 2015-09-09
CY2016047I2 (el) 2017-04-05
JP2012184238A (ja) 2012-09-27
IL229158A0 (en) 2013-12-31
HK1250019A1 (en) 2018-11-23
NO20033651D0 (no) 2003-08-18
IL229160B (en) 2018-08-30
BR0207378A (pt) 2004-06-15
CZ2010473A3 (enExample) 2004-01-14
SI2269604T1 (sl) 2016-11-30
JP6310970B2 (ja) 2018-04-11
KR100695846B1 (ko) 2007-03-19
MX2019010879A (es) 2019-12-16
JP2007284454A (ja) 2007-11-01
CY2019030I2 (el) 2020-05-29
CY2019030I1 (el) 2020-05-29
CZ2019248A3 (cs) 2004-01-14
CA2438504A1 (en) 2002-08-29
PL231418B1 (pl) 2019-02-28
US20040147541A1 (en) 2004-07-29
US20120214774A1 (en) 2012-08-23
CZ2018211A3 (enExample) 2004-01-14
EP1363627A2 (en) 2003-11-26
NO20150895L (no) 2003-10-17
CA2994779A1 (en) 2002-08-29
HUP0303271A3 (en) 2010-09-28
EP2783686A1 (en) 2014-10-01
NO2015010I1 (no) 2015-03-30
EP3342411B1 (en) 2019-08-21
JP6333766B2 (ja) 2018-05-30
NO336110B1 (no) 2015-05-18
LTPA2020503I1 (lt) 2020-03-10
CZ303611B6 (cs) 2013-01-09
DK2269604T3 (en) 2016-11-14
LT3342411T (lt) 2019-09-25
PL414997A1 (pl) 2016-02-29
PT3143995T (pt) 2019-01-17
CA2860306C (en) 2018-04-17
NO335134B1 (no) 2014-09-22
LTPA2019521I1 (lt) 2019-12-10
RU2665138C2 (ru) 2018-08-28
LT2269604T (lt) 2016-11-10
EP3406249A1 (en) 2018-11-28
CA2994779C (en) 2020-08-25
RU2018121314A (ru) 2019-12-10
RU2483727C1 (ru) 2013-06-10
SI2269603T1 (sl) 2015-08-31
NO336208B1 (no) 2015-06-15
EP2764865A3 (en) 2014-10-01
NO343599B1 (no) 2019-04-08
SK288546B6 (sk) 2018-03-05
US8410131B2 (en) 2013-04-02
CN1551767A (zh) 2004-12-01
EP3345602A1 (en) 2018-07-11
IL251270B (en) 2018-06-28
EP3351246B8 (en) 2019-09-18
IL229156A (en) 2017-02-28
DK2269603T3 (en) 2015-08-24
IL229156A0 (en) 2013-12-31

Similar Documents

Publication Publication Date Title
CA2438504C (en) Treatment of solid tumours with rapamycin derivatives
AU2002250968A1 (en) Cancer treatment
HK1250018A1 (en) Rapamycin derivative for treating pancreas cancer
HK1250336A1 (en) Rapamycin derivative for the treatment of a solid tumor associated with deregulated angiogenesis
AU2019222912B2 (en) Cancer treatment
AU2011226833B9 (en) Cancer treatment
AU2011226835B2 (en) Cancer treatment
AU2007201060B2 (en) Cancer treatment
AU2005247029A1 (en) Cancer treatment
HK1232469A1 (en) A rapamycin derivative for treating lung cancer

Legal Events

Date Code Title Description
EEER Examination request